Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen

Annals of Clinical and Laboratory Science

Volumn 33, Issue 1, 2003, Pages 32-38

  Kim, Yonggoo ^a   Lee, Seong ^a   Park, Seungcheol ^a   Jeon, Haemyung ^a   Lee, Wonbae ^a   Kim, Jae Kwang ^a   Cho, Myungok ^a   Kim, Myungshin ^a   Lim, Jihyang ^a   Kang, Chang Suk ^a   Han, Kyungja ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Carcinoembryonic antigen; Colorectal cancer; Fecal analysis; Fecal occult blood; Gastric cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CANCER TISSUE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EARLY DIAGNOSIS; FECES ANALYSIS; FEMALE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL; RELIABILITY; SCREENING TEST; STOMACH CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FECES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037412494     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroentrology 2002;122:1500-1511.
2. Truninger K, Blum HE. Screening for prevention and early detection of colorectal carcinoma. Ther Umsch 2000;57:26-32.
3. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Ann Rev Med 2000;51:511-523.
4. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal anti-inflammatory drugs. Cancer 2002;94:950-963.
5. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998;28:67-81.
6. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
7. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642.
8. Blum HE. Colorectal cancer: Future population screening for early colorectal cancer. Eur J Cancer 1995;31:1369-1372.
9. Winawer SJ, Schottenfeld D, Flehinger BJ. Colorectal cancer screening. J Natl Cancer Inst 1991;83:243-253.
10. Helm JF, Russo MW, Biddle AK, Simpson KN, Ransohoff DF, Sandler RS. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol 2000;95:3250-3258.
11. Ransohoff DF, Sandler RS. Clinical practice. Screening for colorectal cancer. N Eng J Med 2002;346:40-44.
12. Bruzzi JF, Brennan DD, Fenlon HM. Screening for colorectal cancer. N Eng J Med 2002;346:1672-1674.
13. Laghi A, Iannaccone R, Carbone I, Catalano C, Di Giulio E, Schillaci A, Passariello R. Detection of colorectal lesions with virtual computed tomographic colonography. Am J Surg 2002;183:124-131.
14. Sheahan DG, Crissman JD. Immunohistology and cytometry of the gastrointestinal tract. In: Pathology of the Gastrointestinal Tract, 2nd ed (Ming SC, Goldman H, Eds), Williams & Wilkins, Baltimore, 1998; pp 77-78.
15. Chan DW, Sell S. Tumor markers. In: Clinical Chemistry, 3rd ed (Burtis CA, Ashwood ER, Eds), Saunders, Philadelphia, 199; pp 734.
16. Butch AW, Massoll NA, Pappas AA. Tumor markers. In: Clinical Chemistry, 4th ed (Bishop ML, Duben-Engelkirk JL, Fody EP, Eds), Lippincott Williams & Wilkins, Baltimore, 2000; pp 525-526.
17. Friedman RB, Young DS. Effects of Disease on Clinical Laboratory Tests, 3rd ed, AACC Press, Washington, DC, 1997; pp 394-395.
18. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, Hibi K, Goodman SN, D'Allessio M, Paty P, Hamilton SR, Sidransky D, Barany F, Levin B, Shuber A, Kinzler KW, Vogelstein B, Jen J. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-865.
19. Wong NA, Brett L, Stewart M, Leitch A, Longley DB, Dunlop MG, Johnston PG, Lessells AM, Jodrell DI. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma. Br J Cancer 2001;85:1937-1943.
20. Albaugh GP, Iyengar V, Lohani A, Malayeri M, Bala S, Nair PP. Isolation of exfoliated colonic epithelial cells, a novel, non-invasive approach to the study of cellular markers. Int J Cancer 1992;52:347-350.
21. Wenger FA, Zieren J, Peter FJ, Jacobi CA, Muller JM. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langen Arch Surg 1999;384:181-186.
22. Berndt C, Haubold K, Wenger F, Brux B, Muller J, Bendzko P, Hillebrand T, Kottgen E, Zanow J. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem 1998;44:2103-2107.
23. Young GP, St. John JB. Selecting an occult blood test for use as a screening tool for large bowel cancer. Front Gastrointest Res 1991;18:135-156.
24. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365- 1371.
25. Coughlin RJ, Friend WG. Dietary restriction and fecal occult blood testing. Am Fam Phys 1987;35:118-120.
26. Winawer SJ. Screening for colorectal cancer: an overview. Cancer 1980;45:1093-1098.
27. Gilbertson VA, McHugh R, Schuman L, Williams SE. The earlier detection of colorectal cancers: A preliminary report of results of the occult blood study. Cancer 1980;45:2899-2901.
28. Ahlquist DA, Wieand HS, Moertel CG, McGill DB, Loprinzi CL, O'Connell MJ, Mailliard JA, Gerstner JB, Pandya K, Ellefson RD. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993;269:1262-1267.
29. Fugimoto S, Kitsukawa Y, Itoh K. Carcino-embryonic antigen(CEA) in gastric juice or feces as an aid in the diagnosis of gastrointestinal cancer. Ann Surg 1979;189:34-38.
30. Stubbs RS, Nadkarni DM, Monsey HA. Fecal carcinoembryonic antigen (CEA) in patients with large bowel cancer. Eur J Surg Oncol 1987;13:433-436.
31. Matsuoka Y, Matsuo Y, Sugano K, Ohkura H, Kuroki M, Kuroki M. Characterization of carcino-embryonic antigen-related antigens in normal adult feces. Jpn J Cancer Res 1990;81:514-519.
32. Kuroki M, Aruno M, Arakawa F, Wakisaka M, Matsuoka Y. Reaction profiles of seven enzyme immunoassay kits for carcinoembryonic antigen (CEA) analyzed with purified preparations of CEA and related normal antigens. Clin Biochem 1992;25:29-35.
33. Henslee JG, Vachula EJ, Paxton RJ, Matias MS, Shively JE, Rittenhouse HG, Tomita JT. Identification and characterization of new antigenic fragments related to carcinoembryonic antigen in adult feces. Cancer Res 1992;52:4175-4182.
34. Baranov V, Yeung MM, Hammarstroem S. Expression of carcinoembryonic antigen and nonspecific cross-reacting 50-kDa antigen in human normal and cancerous colon mucosa: comparative ultrastructural study with monoclonal antibodies. Cancer Res 1994;54:3305-3314.